SOLVE FSHD Invests US $1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy GAITHERSBURG, Maryland and VANCOUVER, British Columbia – September 29, 2022 – miRecule, Inc., an innovator of next-generation RNA therapeutics, and SOLVE FSHD, a venture-philanthropy organization catalyzing the pace of innovation to accelerate a cure for facioscapulohumeral …
VANCOUVER, B.C., Sept 21, 2022 – SOLVE FSHD, a venture-philanthropy organization catalyzing the pace of innovation to accelerate a cure for FSHD, announced today an investment of US$3 million in Altay Therapeutics; a company focused on developing lifesaving therapies by targeting disease-causing transcription factors. This investment will support Altay Therapeutics’ unique approach to finding an …
VANCOUVER, B.C. – SOLVE FSHD, the venture-philanthropy organization founded by entrepreneur Chip Wilson, announces its financial support to the FSHD Canada Foundation’s strategic investment of US$1.2M in biomarker grant funding to facilitate biomarker research in facioscapulohumeral muscular dystrophy (FSHD). The FSHD Canada Foundation acknowledges the generous support of SOLVE FSHD towards funding these grants. The …
VANCOUVER, B.C. – The world’s most successful entrepreneurs are often willing to share how lessons learned and resilience have shaped their business sense, but few transcend their successes to optimistically forge a path to overcome one’s biggest challenge – their health. Going public with his own story, Wilson, who was diagnosed with Facioscapulohumeral muscular dystrophy …